Elastomeric Pump - Market Insights, Competitive Landscape, and Market Forecast - 2032

Elastomeric Pump Market by Product Type (Continuous Rate Elastomeric Infusion Pumps, Variable Rate Elastomeric Infusion Pumps, and Both), Route of Administration (Intravenous, Subcutaneous, Epidural, and Others), Indication (Pain Management, Antibiotic Therapy, Chemotherapy, and Others), End-User (Hospitals, Ambulatory Surgical Centers, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of chronic diseases, increasing surgical procedures, and technological advancements in product development.

The elastomeric pump market was valued at USD 663.39 million in 2024, growing at a CAGR of 6.72% during the forecast period from 2025 to 2032 to reach USD 1.10 billion by 2032. The demand for elastomeric pumps is growing due to several key factors. These include the increasing prevalence of chronic diseases such as cancer, diabetes, and neurological conditions, and others. The increasing number of surgical procedures performed worldwide also necessitates infusion therapy for patients. Additionally, ongoing technological advancements in product development are enhancing the effectiveness and convenience of these devices. Together, these factors are creating a strong foundation for steady and robust growth in the elastomeric pump market from 2025 to 2032.

Elastomeric Pump Market Dynamics:

According to data from GLOBOCAN (2023), approximately 20 million new cancer cases were reported in 2022, a number projected to rise to 32.6 million by 2045. This increasing cancer burden underscores the rising demand for chemotherapy elastomeric infusion pumps, which are specifically designed to deliver chemotherapy medications. These pumps are typically disposable, single-use devices, individually calibrated for accurate and consistent drug delivery, making them essential in ambulatory oncology care.

Similarly, the global diabetes burden is escalating rapidly. As per the International Diabetes Federation (2023), around 537 million adults (aged 20-79) were living with diabetes in 2021. This number is expected to grow to 643 million by 2030 and 783 million by 2045. Elastomeric pumps play a crucial role in this domain by ensuring continuous and accurate insulin delivery, thereby helping to maintain better glycemic control in outpatient and home settings.

Moreover, the burden of infectious diseases remains a major concern. According to the World Health Organization (2024), an estimated 39.9 million people were living with HIV in 2023, including 1.4 million children (0-14 years) and 38.6 million adults (15+ years).

Additionally, according to the data provided by the World Health Organization (2024), in 2023, an estimated 10.8 million people fell ill with TB worldwide, including 6.0 million men, 3.6 million women, and 1.3 million children. Patients with HIV and similar chronic infections often require long-term intravenous antibiotic therapy, which elastomeric pumps can administer effectively through continuous infusion, particularly in outpatient and home-based care.

Chronic pain management is another major application area. Local anesthetic infusions delivered via elastomeric pumps are frequently used for managing post-operative and chronic pain. According to the European Pain Federation (2023), approximately 150 million people in Europe suffer from chronic pain. These pumps offer an effective, non-electronic solution for delivering pain relief medications over extended periods without the need for hospitalization.

Furthermore, according to data provided by the World Health Organization (2024), in 2022, approximately 2.5 billion adults (18 years and older) were overweight. Of these, 890 million were living with obesity. Additionally, obese patients frequently undergo bariatric surgeries and other procedures that necessitate post-operative pain management, where elastomeric pumps are commonly used to deliver analgesics continuously.

Additionally, the growing number of surgical procedures worldwide is expected to further stimulate demand for elastomeric pumps. According to the data provided by the European Union (2023), there were approximately 1.10 million caesarean sections performed in the EU in 2022. These pumps deliver liquid pain medication directly to the surgical site, helping to manage post-operative pain. For example, data published by the Government of Saskatchewan, Canada, in May 2024 revealed that approximately 95,700 surgeries were performed in the fiscal year 2023-24, representing a notable increase compared to the previous year. As surgical volumes continue to rise, the market for elastomeric pumps is expected to grow in parallel.

However, the limitations and challenges associated with elastomeric pumps and stringent regulatory requirements for device approval, among others, are some of the key constraints that may limit the growth of the elastomeric pump market.

Elastomeric Pump Market Segment Analysis:

Elastomeric Pump Market by Product Type (Continuous Rate Elastomeric Infusion Pumps, Variable Rate Elastomeric Infusion Pumps, and Both), Route of Administration (Intravenous, Subcutaneous, Epidural, and Others), Indication (Pain Management, Antibiotic Therapy, Chemotherapy, and Others), End-User (Hospitals, Ambulatory Surgical Centers, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the elastomeric pump market, the continuous rate elastomeric infusion pumps category is estimated to account for the largest market share in 2024. This growth is primarily driven by the increasing prevalence of chronic diseases and the versatility and clinical advantages offered by continuous rate elastomeric pumps in the treatment and management of such conditions.

One of the key advantages of continuous rate elastomeric pumps is their ability to deliver medication at a predetermined, consistent flow rate, ensuring stable plasma drug concentrations. This makes them ideal for therapies where maintaining steady-state drug levels is crucial, such as in the administration of antibiotics, analgesics, and chemotherapy agents. For instance, elastomeric pumps are widely used in outpatient parenteral antibiotic therapy (OPAT), as they provide portable, non-electronic infusion without the need for external power sources or complex tubing systems. A notable example is the SMARTeZ® disposable elastomeric pump developed by Progressive Medical, Inc., designed for both intermittent and continuous antibiotic infusion as well as general infusion therapies.

Technological advancements in elastomeric pump design have significantly enhanced their usability, durability, and safety. These innovations have led to the development of pumps with extended drug stability and storage capabilities, enabling them to be refrigerated or even frozen without compromising performance. One of the key benefits of these advanced devices is the incorporation of pre-set flow rates, which help minimize the risk of incorrect dosing, a common concern with electronic infusion pumps.

Furthermore, continuous elastomeric pumps are self-powered through an internal elastic balloon, eliminating the need for batteries or external power sources. Their low-maintenance design reduces the likelihood of mechanical failure, making them highly reliable. These features, combined with their portability and ease of use, make these pumps suitable for a wide range of clinical settings.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of elastomeric pump across the globe.

North America is expected to dominate the overall elastomeric pump market:

North America is projected to hold the largest share of the elastomeric pump market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of chronic diseases, a highly advanced healthcare infrastructure, and the strong presence of key market players. Collectively, these factors are positioning North America as the leading market in the global elastomeric pump market.

According to data from the International Agency for Research on Cancer (2025), the number of new cancer cases in the U.S. was 2,380,189 in 2022, with projections indicating a significant rise to 3,380,124 cases by 2045. Among these, leukemia had 63,100 new cases in 2022, expected to increase to 88,600 by 2045. Similarly, data from the Canadian Cancer Society (2024), over 6,600 people were diagnosed with leukemia in Canada. Cancer treatments often require continuous delivery of chemotherapy, targeted therapies, and immunotherapy, making elastomeric infusion pumps an essential tool in oncology care.

According to the American Heart Association (2024), more than 29.3 million adults have been diagnosed with diabetes, while an estimated 9.7 million remain undiagnosed. Furthermore, 115.9 million Americans were reported to be living with pre-diabetes as of 2021. Elastomeric pumps play a critical role in insulin therapy by delivering precise and continuous doses needed to maintain stable blood glucose levels, particularly in patients requiring intensive insulin regimens.

Furthermore, as per the Centers for Disease Control and Prevention (2023), approximately 20.9% of adults, or 51.6 million people, experienced chronic pain in 2022. Of these, 6.9% (17.1 million people) suffered from high-impact chronic pain that significantly limits daily activities. Elastomeric pumps, often used for continuous infusion of pain-relieving medications, are increasingly being adopted in pain management strategies, especially for patients dealing with long-term, non-cancer-related pain.

Additionally, as per the data provided by the U.S Department of Health and Human Services (2023), it was stated that about 23 million Americans visit a doctor's office or clinic seeking treatment for infections every year.

In addition to the growing disease burden, North America benefits from an advanced healthcare infrastructure, which supports the widespread adoption of advanced infusion technologies. The presence of leading medical device manufacturers and key market players further strengthens the region's position in the global elastomeric pump market.

Collectively, these factors, such as rising chronic disease prevalence, strong clinical demand, and robust healthcare infrastructure, are expected to significantly drive the growth of the North America elastomeric pump market during the forecast period.

Elastomeric Pump Market Key Players:

Some of the key market players operating in the elastomeric pump market include B.Braun Melsungen AG, Baxter, Nipro Corporation, DAIKEN MEDICAL CO., LTD., Gamastech Innovative Infusion Systems, Vikymed Italia srl, PAJUNK, Ace Medical, McKesson Corporation, MULTIMEDICAL S.r.l., Progressive Medical, Inc., Vygon Group, Promecon GmbH, Preferred Medical, Adriamed SRL, FLOWONIX MEDICAL INC., Smiths Group plc, Fresenius SE & Co. KGaA, Avanos Medical, Inc., Intera Oncology, and others.

Recent Developmental Activities in the Elastomeric Pump Market:

• In May 2024, Arecor Therapeutics plc announced a research collaboration with Medtronic to develop a novel, high-concentration, thermostable insulin for use in a next-generation pump. Through this collaboration, both companies bring advancements in insulin treatment to enhance patient care by providing insulin that reduces the need for pump maintenance interventions. This could broaden its utility for physicians and lead to significant healthcare cost savings.  

Key takeaways from the elastomeric pump market report study

• Market size analysis for the current elastomeric pump market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the elastomeric pump market.
• Various opportunities available for the other competitors in the elastomeric pump market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current elastomeric pump market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the elastomeric pump market growth in the future?

Target audience who can benefit from this elastomeric pump market report study

• Elastomeric pump product providers
• Research organizations and consulting companies
• Elastomeric pump-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in elastomeric pumps
• Various end-users who want to know more about the elastomeric pump market and the latest technological developments in the elastomeric pump market.

Frequently Asked Questions for the Elastomeric Pump Market:

1. What is an elastomeric pump?

• Elastomeric pump, also known as a balloon pump or elastomeric infusion pump, is a non-electronic, disposable medical device used to deliver continuous, controlled volumes of medication to a patient over a set period of time.

2. What is the market for an elastomeric pump?

• The elastomeric pump market was valued at USD 663.39 million in 2024, growing at a CAGR of 6.72% during the forecast period from 2025 to 2032 to reach USD 1.10 billion by 2032.

3. What are the drivers for the elastomeric pump market?

• The demand for elastomeric pumps is growing due to several key factors. These include the increasing prevalence of chronic diseases such as cancer, diabetes, and neurological conditions, and others. There is also a rising shift toward home healthcare, as these pumps allow patients to receive infusion therapy at home. Additionally, ongoing technological advancements in product development are enhancing the effectiveness and convenience of these devices. Together, these factors are creating a strong foundation for steady and robust growth in the elastomeric pump market from 2025 to 2032.

4. Who are the key players operating in the elastomeric pump market?

• Some of the key market players operating in the elastomeric pump market include B.Braun Melsungen AG, Baxter, Nipro Corporation, DAIKEN MEDICAL CO., LTD., Gamastech Innovative Infusion Systems, Vikymed Italia srl, PAJUNK, Ace Medical, McKesson Corporation, MULTIMEDICAL S.r.l., Progressive Medical, Inc., Vygon Group, Promecon GmbH, Preferred Medical, Adriamed SRL, FLOWONIX MEDICAL INC., Smiths Group plc, Fresenius SE & Co. KGaA, Avanos Medical, Inc., Intera Oncology, and others.

5. Which region has the highest share in the elastomeric pump market?

• North America is projected to hold the largest share of the elastomeric pump market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of chronic diseases, a highly advanced healthcare infrastructure, and the strong presence of key market players. Collectively, these factors are positioning North America as the leading market in the global elastomeric pump market.

This product will be delivered within 2 business days.